Shin, D M <br/><br/>
Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  1991 
 - 145-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0344-5704 
<br/><br/><label>Standard No.: </label>10.1007/BF00687325  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Depsipeptides<br/>Drug Administration Schedule<br/>Drug Evaluation<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Muscles--drug effects<br/>Neuromuscular Junction--drug effects<br/>Peptides, Cyclic--administration & dosage